Tuesday, March 15, 2011 10:22:45 AM
In a note to clients, J.P. Morgan writes, "With positive data in both advanced and naïve Parkinson's patients and 066 licensed to GSK outside of the US, Impax's investment in its branded business is beginning to show a return. We now see IPX 066 as a derisked asset that could have the potential to bring in more than $150 million in annual revenue with little further R&D outlay."
Source: http://www.benzinga.com/analyst-ratings/analyst-color/11/03/926828/j-p-morgan-maintains-overweight-on-impax-laboratories-ipx#ixzz1Gg6YisWk
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM